

Laboratory Control Sample Summary

Client: Tris Pharma, Inc.

SDG No.: Q2902

Project: Quarterly

Run No.: LB136892

Analyte	Units	True Value	Result	Conc. Qualifier	% Recovery	Dilution Factor	Acceptance Limit %R	Analysis Date
Sample ID	LB136892BS							
Non-Polar Material	mg/L	20.0	16.9		84	1	78-114	08/20/2025

Laboratory Control Sample Summary

Client: Tris Pharma, Inc.

SDG No.: Q2902

Project: Quarterly

Run No.: LB136892

Analyte	Units	True Value	Result	Conc. Qualifier	% Recovery	Dilution Factor	Acceptance Limit %R	Analysis Date
Sample ID	LB136892BSD							
Non-Polar Material	mg/L	20.0	17.0		85	1	78-114	08/20/2025

Laboratory Control Sample Summary

Client: Tris Pharma, Inc.

SDG No.: Q2902

Project: Quarterly

Run No.: LB136897

Analyte	Units	True Value	Result	Conc. Qualifier	% Recovery	Dilution Factor	Acceptance Limit %R	Analysis Date
Sample ID	LB136897BS							
BOD5	mg/L	198	186		94	1	84.6-115.4	08/20/2025

Laboratory Control Sample Summary

Client: Tris Pharma, Inc.

SDG No.: Q2902

Project: Quarterly

Run No.: LB136903

Analyte	Units	True Value	Result	Conc. Qualifier	% Recovery	Dilution Factor	Acceptance Limit %R	Analysis Date
Sample ID	LB136903BS							
TSS	mg/L	550	533		97	1	90-110	08/20/2025

Laboratory Control Sample Summary

Client: Tris Pharma, Inc.

SDG No.: Q2902

Project: Quarterly

Run No.: LB136918

Analyte	Units	True Value	Result	Conc. Qualifier	% Recovery	Dilution Factor	Acceptance Limit %R	Analysis Date
Sample ID	LB136918BS							
COD	mg/L	50	49.9		100	1	90-110	08/22/2025